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Perceived Family Support and
Antiretroviral Adherence in
HIV-Positive Individuals: Results from a
Community-Based Positive Living With
HIV Study
Krishna C. Poudel, David R. Buchanan, Rachel M.
Amiya, and Kalpana Poudel-Tandukar
Abstract
The purpose of this study was to examine the association between perceived family
support, either positive or negative, and adherence to antiretroviral medication
regimens among HIV-positive individuals in the Kathmandu Valley, Nepal. We measured past 3-month antiretroviral adherence among 233 HIV-positive individuals, in
relation to perceived family support, both positive (in terms of emotional and instrumental support) and negative (in the form of negative interactions), using the 10-item
Nepali Family Support and Difficulty Scale. Medium and high levels of perceived
emotional support from family were associated with reduced risk of antiretroviral
nonadherence, compared with low levels of perceived emotional support (adjusted
odds ratio [AOR] ¼ 0.37, 95% confidence interval [CI] [0.16, 0.88], and AOR ¼ 0.23,
95% CI [0.08, 0.64], respectively). Conversely, higher levels of felt emotional distance
(AOR ¼ 1.46, 95% CI [1.00, 2.14]) and experienced physical harm (AOR ¼ 2.04, 95%
CI [1.07, 3.91]) were associated with increased risk of nonadherence. The results
support the recommendation that service providers need to be aware of the significant role of family support in shaping antiretroviral adherence and to consider ways
to strengthen positive family support while minimizing negative family interactions to
increase adherence rates.

Keywords
family, social support, antiretroviral therapy, medication adherence, HIV or
AIDS, Nepal
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Background
Promoting and sustaining long-term medication adherence among HIV-positive
individuals has become an important element of modern HIV care. Globally, the
availability of antiretroviral therapy (ART) is associated with reduced rates of
morbidity and mortality as well as improved quality of life for HIV-positive
individuals.1–4 To realize the full beneﬁts of ART, however, it is important for
HIV-positive individuals to maintain high levels of medication adherence.5–8
Dramatic increases in viral load have been found within days of treatment
withdrawal or missed antiretroviral doses.9 Moreover, irregular adherence to
medication can lead to treatment failure as well as to the development of
drug-resistant strains of HIV.10
Family support has a potentially important role to play in promoting ART
adherence among HIV-positive individuals. Studies have found a positive association between measures of family support and ART adherence.11–14 Such
results indicate that familial ties play an important role in health behaviors,
through illness adaptation,15 coping,16 and medical or health care utilization.17
Similarly, a supportive family environment has been found to decrease diseaserelated negative aﬀect18,19 among HIV-positive individuals, particularly for
those harboring fears about the prospect of isolation and rejection by family
members.20–22
Conversely, other studies have found nonsigniﬁcant23 or negative eﬀects of
family interactions on ART adherence among HIV-positive individuals when
there is a fear of stigma and discrimination.24–26 In families with low levels of
attachment, aﬀected individuals may not discuss personal issues,27 including
HIV diagnosis, ART initiation, or use of antiretroviral medicines. Often,
HIV-positive individuals may not disclose their health status to family
members,28 leading to a lack of family support to improve medication adherence
and other health outcomes. These ﬁndings underscore the importance of investigating the inﬂuence of both positive and negative aspects of family support on
ART adherence. Yet, few studies have examined the potential impacts of positive and negative interactions within familial relationships simultaneously.
To ﬁll this gap, we explored the association between both perceived positive
and perceived negative family support and ART nonadherence among HIVpositive individuals in the Kathmandu Valley, Nepal. The ﬁndings of this
study will be useful in developing more carefully tailored interventions to promote ART adherence and, thereby, to maintain favorable treatment outcomes
over the long term.
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Methods
Design and Participants
This study is based on data from the Positive Living with HIV study, a longitudinal study conducted among HIV-positive individuals in the Kathmandu
Valley, Nepal, details of which have been reported elsewhere.29–33 The
Kathmandu Valley consists of three districts (Kathmandu, Bhaktapur, and
Lalitpur) with an estimated population of 2.5 million in 2011.34 Nepal shares
several common characteristics with other resource-limited countries in Asia,
including a high burden of HIV among the high-risk populations but low prevalence in the general population, and low ART coverage.35 Although overall HIV
prevalence was 0.3% in 2011, with an estimated 50,200 adults (aged 15–49 years)
living with HIV,36 reported HIV prevalence was much higher among certain
high-risk populations, including injection drug users (6.3%) and female sex
workers (4.2%).37 Regarding treatment coverage, free ART services were introduced in the country in 2004, but coverage of eligible individuals was only 23.7%
in 2011.37 Seven of the 44 total ART sites in the country are located in the
Kathmandu Valley.38 Several nongovernmental organizations (NGOs) have
been assisting these sites by facilitating the hospital visits of HIV-positive individuals for consultation, ART initiation, CD4+ cell count monitoring, and
other services.32 As necessary, these NGOs also collect antiretroviral medicines
for their registered members from the designated ART clinic and distribute them
to their homes.
In February–March 2010, we recruited 322 participants through a network
of ﬁve NGOs working with HIV-positive individuals in the Kathmandu
Valley. The inclusion criteria for participants were as follows: aged 18 to 60
years, self-reported diagnosis of HIV-positive status, residence in the
Kathmandu Valley, and willingness to participate in the study voluntarily.
For this study, participants who were not under ART were excluded, resulting
in a ﬁnal study population of 233 HIV-positive individuals (122 men and 111
women).

Procedures
Data were collected by face-to-face interview using a structured questionnaire
administered in Nepali. Adopting items from previous studies conducted in
Nepal,39–42 the questionnaire was ﬁrst developed in English. Additional questions were then translated into the Nepali language and back-translated into
English for veriﬁcation of semantic equivalence. The Nepali version was revised
based on back-translation, pretested among 30 participants, and ﬁnalized on the
basis of the pretest results.
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Four interviewers were hired for data collection. The ﬁrst author provided a
day-long training on the contents of the questionnaire and interview techniques.
Using the Nepali language questionnaire, the interviewers conducted in-person
interviews individually in a private setting. Each interview lasted approximately
45 to 60 minutes. Each participant received 100 Nepali rupees (approximately
US $1.35) to cover transportation costs. The ﬁrst and last authors supervised the
ﬁeldwork. They organized review sessions at the end of each day with all the
ﬁeld-team members. In these sessions, they reemphasized the importance of
reassuring participants of the conﬁdentiality of their information, checking the
completeness of the survey prior to interview completion, and asking questions
to each participant in the same manner to minimize within – and betweenparticipant variability.

Measures
Perceived family support. As reported earlier,43,44 perceived family support was
measured using the 10-item Nepali Family Support and Diﬃculty Scale
(a ¼ .87) speciﬁcally developed for use in Nepal.45 The items measured participants’ perceptions of both support from and negative interactions with family
members in the past year. Response categories ranged from 0 Not at all to 3 All
the time. Before analysis, we reversed the scores for negatively formulated items
measuring negative family interaction. Then, we obtained the total perceived
family support scores by summing all 10 items. With a range of 0 to 30,
higher scores indicated higher levels of perceived family support. Finally, the
total score was categorized by tertiles into high (27–30), medium (23–26), and low
(0–22) levels for statistical analyses.
To measure speciﬁc dimensions of family support, the scale was further
divided into three subscales: emotional support (four items, a ¼ .79, e.g.,
“How much can you share your feelings with your family members?”), instrumental support (two items, a ¼ .66, e.g., “How much does your family meet
your basic needs?”), and negative interaction (four items, a ¼ .74, e.g., “How
much do you feel your family has physically hurt you?”). Similar to overall
scores, total scores on each subscale were categorized as high, medium, and
low by tertiles.

ART adherence. ART adherence was measured by asking participants to recall
their intake of prescribed doses of antiretroviral medicines in the previous 3
months. To minimize recall bias, ﬁrst, participants were asked how many doses
of antiretroviral medicines they had missed over the previous 4 days. Then, they
were asked if they forgot to take antiretroviral medicines over the previous 1
month, 2 months, and 3 months. As complete adherence is considered essential
in stopping HIV replication,5 participants who reported never forgetting to take
their antiretroviral medicines in the past 3 months were considered as adherent,
while those who reported forgetting at least one dose during that same period
were categorized as nonadherent for the purposes of our study.
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Covariates. Adopting questionnaire items from those used in previous studies,39–42 we measured key sociodemographic, drug and alcohol use, and HIVspeciﬁc clinical and psychological factors that might have potential associations
with ART adherence. We categorized participants’ education into Up to primary
or Secondary or higher levels from the reported years of formal education.
Similarly, we categorized participants’ employment status as Employed or
Unemployed from participants’ reports of their speciﬁc types of work. We
asked participants if they had disclosed their HIV status to any family members
(Yes or No). Participants’ current smoking status (Smoker or Nonsmoker) was
classiﬁed based on reported smoking frequency.46 We asked participants if they
had used any illicit drugs in the past 6 months (Yes or No) and if they had
consumed alcohol in the past 30 days (Yes or No). We assessed illness history by
asking, “In the past 12 months, did you suﬀer from any type of disease including
minor illnesses?” (Yes or No).
As reported elsewhere,47 we measured HIV symptom burden using a 16-item
HIV Symptom Index based on a 1-month recall period (a ¼ .92). The original
scale had 20 items.48 However, we omitted four items (Sadness, Anxiety, Sleep
trouble, and Sex problems) to avoid overlap with items in the measure of depressive symptoms. The items had a 5-point response scale ranging from 0 I don’t
have this problem to 4 I have this problem and It bothers me a lot. We obtained the
total score for the scale by summing the scores of all 16 items. We then categorized the score level as high (above the median) or low (below or equal to the
median) for statistical analysis.
We measured internalized stigma using a seven-item scale (a ¼ .74) adopted
from a previous study carried out among HIV-positive individuals49 (e.g., “I am
ashamed that I am HIV-positive”). Participants indicated either agreement (1) or
disagreement (0) with each of the scale items. We obtained the total score for
internalized stigma by summing the scores of all seven items, with higher scores
suggesting a greater burden of felt stigma. Finally, the score was categorized as
high (equal to or above the median) or low (below the median) for statistical
analysis.

We used the 21-item Beck Depression Inventory-I, Nepali version50,51 to
assess depressive symptoms over the past 2 weeks (a ¼ .89). Participants
responded to the items on a 4-point Likert scale, with a total range for the instrument of 0 to 61. The Nepali version of the scale has been validated for use in
Nepal.50 Results from the validation study indicate that a score of 20 or higher
indicates moderate to severe depression requiring mental health intervention.
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Statistical Analyses
First, we report proportions for sociodemographic, health, alcohol, drug, and
ART adherence-related variables, as well as mean and standard deviation
(SD), or median and interquartile range (IQR) as appropriate. Second, we
compared participant characteristics according to reported high, medium, or
low levels of perceived family support. Third, we tested the association
between perceived family support and ART nonadherence using bivariate
and multivariable logistic regression analyses to estimate AORs with 95%
CIs. For this, we ﬁrst examined the bivariate associations between each covariate and ART nonadherence. As Katz52 recommends, we then performed
multivariable logistic regression analysis including all covariates that had a
bivariate p value  .10. Our ﬁnal multivariable model adjusted for ART duration, illicit drug use, depressive symptoms, and perceived family support.
Fourth, we examined associations of the emotional support, instrumental support, and negative interaction subscale scores with ART nonadherence using
multivariable logistic regression analyses adjusting for ART duration, illicit
drug use, and depressive symptoms. Finally, we examined the association of
each individual perceived family support item with ART nonadherence using
multivariable logistic regression analyses. We used SPSS Statistics 22.0 (SPSS
Inc., Chicago, USA) to perform all of the analyses, with statistical signiﬁcance
set at p < .05.

Ethical Considerations
All participants were individually informed of the study procedures using a
prepared information sheet, after which they voluntarily provided written
informed consent to participate in the study. All interviews were conducted
in a private setting. Prior to each interview, interviewers reassured participants
of the conﬁdentiality of their personal information, protections reinforced
by using numerical codes in place of names in all records. The study procedures were approved by the Research Ethics Committee of the Nepal
Health Research Council in Kathmandu, Nepal; the National Center for
Global Health and Medicine in Tokyo, Japan; Waseda University in Tokyo,
Japan; and the institutional review board of the University of Massachusetts
Amherst.
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Results
General Characteristics
The mean age of the participants was 35.2 (SD ¼ 7.1) years. The median duration since testing positive for HIV was 53 (IQR ¼ 24–95) months. Overall,
52.4% of participants were men, 71.2% were currently married, 69.1% were
employed, and 21.2% reported illicit drug use in the past 6 months (Table 1).
With respect to the ART regimen, 226 (96.3%) of participants were on two
Nucleoside Reverse Transcriptase Inhibitors (NRTI; either Lamivudine and
Zidovudine or Lamivudine and Stavudine) and one Nonnucleoside Reverse
Transcriptase Inhibitor (either Efavirenz or Nevirapine); six (2.6%) participants
were on two NRTI (Tenofovir and Didanosine) and one Protease Inhibitor
(Lopinavir or Ritonavir); and one (0.4%) participant was on three NRTI
(Abacavir, Zidovudine, and Lamivudine). The median duration on antiretroviral treatment was 24 months (IQR ¼ 9–39). Nearly two thirds of participants
reported a history of disease in the past 12 months. The mean score (SD) for
internalized stigma was 10.9 (2.2).

Characteristics of Participants by Perceived Family Support
The mean score for perceived family support was 22.5 (SD ¼ 6.2). Higher proportions of women and currently single participants reported low levels of perceived family support (Table 2). In addition, higher proportions of participants
with lower levels of education, with a history of any disease in the past 12
months, and with higher levels of internalized stigma reported low levels of
perceived family support.

Rates of ART Nonadherence
None of the participants reported missing any doses of antiretroviral medicines in
the past 4 days. Seven participants (3.0%) reported missing at least one dose of
antiretroviral medicines during the past week. Nine participants (3.9%) reported
missing doses of antiretroviral medicines in the past month, 18 participants
(7.7%) in the past 2 months, and 41 participants (17.6%) in the past 3 months.

Association Between Perceived Family Support and ART
Nonadherence
A higher proportion of participants with low levels of perceived family support
reported a history of missing antiretroviral medication doses in the past
3 months; the nonadherence rate among those with low levels of perceived
family support was 25.6%, whereas the rates among those with medium and
high levels of perceived family support were 15.9% and 9.2%, respectively
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Table 1. Demographic and Health Characteristics of Participants (N ¼ 233).
Characteristic
Age (years)
20–34
35–60
Sex
Female
Male
Current marital status
Single
Married
Educationa
Up to primary
Secondary or higher
Employed
No
Yes
Months since testing HIV positive
1–52
53+
HIV disclosure to any family memberb
No
Yes
Illicit drug use, past 6 months
No
Yes
Current smoker
No
Yes
Alcohol use, past 30 days
No
Yes
Current antiretroviral therapy regimen
Lamivudine, Zidovudine, and Nevirapine
Lamivudine, Zidovudine, and Efavirenz
Lamivudine, Stavudine, and Nevirapine
Lamivudine, Stavudine, and Efavirenz
Tenofovir, Didanosine, and Lopinavir or Ritonavir
Abacavir, Zidovudine, and Lamivudine

n

(%)

119
114

(51.1)
(48.9)

111
122

(47.6)
(52.4)

67
166

(28.8)
(71.2)

105
126

(45.5)
(54.5)

72
161

(30.9)
(69.1)

116
117

(49.8)
(50.2)

40
190

(17.4)
(82.6)

207
26

(88.8)
(21.2)

137
96

(58.8)
(41.2)

212
21

(91.0)
(9.0)

117
61
44
4
6
1

(50.2)
(26.2)
(18.9)
(1.7)
(2.6)
(0.4)
(continued)
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Table 1. Continued.
Characteristic
Months on antiretroviral therapy
1–23
24+
History of any disease in past 12 months
No
Yes

n

(%)

114
119

(48.9)
(51.1)

83
150

(35.6)
(64.4)

a

Two participants did not respond to this question.
Three participants did not respond to this question.

b

(Table 3). In bivariate logistic regression analysis, low levels of perceived family
support were associated with increased risk of ART nonadherence compared
with high levels of perceived family support (OR ¼ 3.38, 95% CI [1.28, 8.91]). In
multivariable logistic regression analysis, those with low levels of perceived
family support had 3.39-fold higher odds of reporting ART nonadherence compared with those with high levels of perceived family support. Similarly, those
participants who had been on antiretroviral treatment for longer durations and
who reported illicit drug use were more likely to report a history of ART
nonadherence.
Table 4 shows the results of multivariable analyses for perceived family support subscale scores and individual items associated with ART nonadherence. Of
the three subscales, only emotional support was statistically associated with ART
nonadherence; namely, reporting medium (AOR ¼ 0.37, 95% CI [0.16, 0.88]) and
high (AOR ¼ 0.23, 95% CI [0.08, 0.64]) levels of emotional support were associated with reduced risk of ART nonadherence compared with reporting low
levels of emotional support. All four items of emotional support were signiﬁcantly
associated with ART adherence after adjusting for potential confounders.
Conversely, two negative interaction items were statistically associated with
ART nonadherence. Higher levels of felt emotional distance from family was
associated with increased risk of ART nonadherence (AOR ¼ 1.46, 95%
CI [1.00, 2.14]). Similarly, a history of higher levels of physical harm by family
members was associated with increased risk of ART nonadherence (AOR ¼ 2.04,
95% CI [1.07, 3.91]). In addition, a higher proportion (n ¼ 6, 40.0%) of participants who reported the experience of more frequent physical harm from family
had not disclosed their HIV status to their families than among those who
reported less frequent physical harm from family (n ¼ 34, 15.8%, p ¼ .017).

Discussion
This study revealed that the experience of a low level of perceived family support—emotional support, in particular—was associated with increased risk of
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Table 2. Sociodemographic and Health Characteristic of Participants According to
Reported Level of Perceived Family Support (N ¼ 233).
Perceived family support levela
High (n ¼ 65) Medium (n ¼ 82) Low (n ¼ 86)
Variable
Age (years)
20–34
35–60
Sex
Female
Male
Current marital status
Single
Married
Educationb
Up to primary
Secondary or higher
Employed
No
Yes
Months since testing HIV positive
1–52
53+
HIV disclosure to any family memberc
No
Yes
Illicit drug use, past 6 months
No
Yes
Current smoker
No
Yes
Alcohol use, past 30 days
No
Yes

n

(%)

n

(%)

n

(%)

p

29
36

(24.4)
(31.6)

43
39

(36.1)
(34.2)

47
39

(39.5)
(34.2)

.452

16
49

(14.4)
(40.2)

35
47

(31.5)
(38.5)

60
26

(54.1)
(21.3)

<.001

13
52

(19.4)
(31.3)

18
64

(26.9)
(38.6)

36
50

(53.7)
(30.1)

.003

17
47

(16.2)
(37.3)

38
44

(36.2)
(34.9)

50
35

(47.6)
(27.8)

<.001

17
48

(23.6)
(29.8)

26
56

(36.1)
(34.8)

29
57

(40.3)
(35.4)

.597

32
33

(27.6)
(28.2)

43
39

(37.1)
(33.3)

41
45

(35.3)
(38.5)

.822

6
58

(15.0)
(30.5)

13
69

(32.5)
(36.3)

21
63

(52.5)
(33.2)

.041

55
10

(26.6)
(38.5)

74
8

(35.7)
(30.8)

78
8

(37.7)
(30.8)

.442

33
32

(24.1)
(33.3)

47
35

(34.3)
(36.5)

57
29

(41.6)
(30.2)

.150

57
8

(26.9)
(38.1)

77
5

(36.3)
(23.8)

78
8

(36.8)
(38.1)

.423

(continued)
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Table 2. Continued.
Perceived family support levela
High (n ¼ 65) Medium (n ¼ 82) Low (n ¼ 86)
Variable

n

History of any disease, past 12 months
No
28
Yes
37
Months on antiretroviral therapy
1–23
30
24+
35
Internalized stigma score (Median: 11)
Low (7–10)
42
High (11–14)
23

(%)

n

(%)

n

(%)

p

(33.7)
(24.7)

34
48

(41.0)
(32.0)

21
65

(25.3)
(43.3)

.023

(26.3)
(29.4)

38
44

(33.3)
(37.0)

46
40

(40.4)
(33.6)

.567

(41.6)
(17.4)

34
48

(33.7)
(36.4)

25
61

(24.8)
(46.2)

<.001

a

Perceived family support scores (High: 27–30, Medium: 23–26, and Low: 0–22).
Two participants did not respond to this question.
c
Three participants did not respond to this question.
b

ART nonadherence among the surveyed HIV-positive individuals. Moreover,
more frequent experience of physical harm by family and higher levels of felt
emotional distance from family members was associated with increased risk of
ART nonadherence. To our knowledge, this is the ﬁrst study exploring the
association of both positive and negative aspects of family support with ART
adherence among HIV-positive individuals, while adjusting for potential
confounders.
Adding to existing literature on the positive association between overall
family support and ART adherence,11–14 our study provides further information
on the distinct roles of both positive and negative elements of family support on
ART adherence among HIV-positive individuals. In our study, positive forms of
family support, particularly in the emotional domain, appear to be protective
toward improving ART adherence. As reported by previous studies,18,19 perception of a supportive family environment in the form of felt emotional support is
likely to decrease negative aﬀect associated with the disease, probably by
increasing self-esteem and adaptive coping. High levels of family attachment
and adaptiveness are expected in a positive family environment, as reﬂected in
the items of the emotional support subscale. Family members residing in such an
environment are likely to adapt better to unexpected events and transitions27
such as HIV diagnosis, treatment initiation, and adverse side eﬀects or setbacks
in the disease progression. Furthermore, HIV or AIDS-related knowledge and
treatment may be expected to be better absorbed53 and used to maintain medication adherence in such environments.
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Table 3. Odds Ratios and 95% CIs for ART Nonadherence by Level of Perceived Family
Support (N ¼ 233).
ART nonadherence
Yes
Variable

n

Perceived family support
High (27–30)
6

No
(%)

n

(%)

OR

(95% CI)

AOR

(95% CI)

P

(9.2)

59

(90.8)

Medium (23–26)

13

(15.9)

69

(84.1)

1.85

(0.66–5.17)

1.86

(0.63–5.46)

0.259

Low (0–22)

22

(25.6)

64

(74.4)

3.38

(1.28–8.91)

3.39

(1.19–9.65)

0.022

Age (in years)
20–34

25

(21.0)

94

(79.0)

16

(14.0)

98

(86.0)

0.61

(0.30–1.22)

Sex
Female

22

(19.8)

89

(80.2)

Male

19

(15.6)

103

(84.4)

0.74

(0.38–1.96)

0.84

(0.40–1.74)

0.95

(0.48–1.88)

1.27

(0.59–2.70)

1.69

(0.85–3.38)

2.09

(1.03–4.24)

3.01

(1.38–6.56)

0.005

0.97

(0.39–2.38)

2.34

(0.94–5.83)

3.17

(1.15–8.69)

0.025

1.45

(0.73–2.86)

1.11

(0.35–3.49)

35–60

Current marital status
Single
Married
Educationa
Up to primary

13

(19.4)

54

(80.6)

28

(16.9)

138

(83.1)

19

(18.1)

86

(81.9)

22

(17.5)

104

(82.5)

11

(15.3)

61

(84.7)

30

(18.6)

131

(81.4)

Months since testing HIV positive
1–52
16 (13.8)

Secondary or higher
Employed
No
Yes

100

(86.2)

25

(21.4)

92

(78.6)

ART duration (in months)
1–23
14

(12.3)

100

(87.7)

(22.7)

92

(77.3)

53+

24+

27

HIV disclosure to any family member
No
7
(17.5)

33

(82.5)

(17.9)

156

(82.1)

Illicit drug use, past 6 months
No
33 (15.9)

Yes

34

174

(84.1)

8

(30.8)

18

(69.2)

21

(15.3)

116

(84.7)

20

(20.8)

76

(79.2)

Alcohol use, past 30 days
No
37

(17.5)

175

(82.5)

(19.0)

17

(81.0)

Yes
Current smoker
No
Yes

Yes

4

(continued)
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Table 3. Continued.
ART nonadherence
Yes

No

Variable

n

(%)

n

(%)

OR

(95% CI)

AOR

(95% CI)

P

Depressive symptoms
No (BDI-I < 20)
Yes (BDI-I  20)

23
18

(13.8)
(17.3)

144
48

(86.2)
(72.7)

2.34

(1.16–4.71)

2.10

(0.97–4.54)

0.059

HIV symptom burden
Low (16–32)

16

(13.7)

101

(86.3)

25

(21.6)

91

(78.4)

1.73

(0.87–3.45)

History of any disease, past 12 months
No
13 (15.7) 70

(84.3)
1.23

(0.60–2.54)

1.24

(0.62–2.47)

High (33–64)

Yes

28

(18.7)

122

(81.3)

Internalized stigma score
Low (7–10)
16

(15.8)

85

(84.2)

(18.9)

107

(81.1)

High (11–14)

25

Note. AOR ¼ adjusted odds ratio; CI ¼ confidence interval; OR ¼ odds ratio; ART ¼antiretroviral therapy;
BDI-I ¼ Beck Depression Inventory-I.
a
Two participants did not respond to this question.

In terms of negative family interactions, higher levels of physical harm by family
and higher levels of felt emotional distance from family signiﬁcantly increased the
likelihood of ART nonadherence among our participants. The familial relationships
can be a source of tension in families with low levels of attachment27 or having
frequent negative interactions. In such environments, family members may not be
helpful in supporting individuals to accept their HIV diagnosis, transition smoothly
to ART initiation, or maintain consistent ART adherence. One previous study
reported a negative eﬀect of home-based peer adherence support on treatment
outcomes among HIV-positive individuals residing in the most vulnerable or dysfunctional families.54 Some HIV-positive individuals in such families may not disclose their HIV status to their family members. In our study, for example, a
signiﬁcantly higher proportion of the participants who reported experiencing physical harm by their family members had not disclosed their HIV status to any of their
family members. However, a history of HIV nondisclosure was not statistically
associated with increased risk of ART nonadherence among our participants.
Similar to the results of previous studies carried out in China55 and India,56
we found that HIV-positive individuals on ART for longer periods were at
signiﬁcantly increased risk of ART nonadherence compared with those on
ART for shorter periods. Unlike our study, however, a separate independent
study conducted in Kathmandu did not ﬁnd any statistical association between
the length of ART and ART adherence.57 The diﬀerences in participant

14
Table 4. Multiple Logistic Regression Analyses on the Association Between Individual
Perceived Family Support Items and ART nonadherence (N ¼ 233)a.
Itemb
Emotional support
Feeling shown love and caring by family
Feeling have an important role in family
Feeling involved in family decision making
Feeling able to share feelings with family
Total emotional support score
High (10–12)
Medium (7–9)
Low (0–6)
Instrumental support
Feeling basic needs (food/clothes) met in family
Feeling supported by family when sick
Total instrumental support score
High (6)
Medium (5)
Low (0–4)
Negative interaction
Feeling disliked by family
Feeling (emotionally) distant from family
Having been physically hurt by family member(s)
Feeling exploited (for household and farming) by family
Total negative interaction score
High (12)
Medium (11)
Low (0–10)

AOR

(95% CI)

P

0.65
0.61
0.69
0.62

(0.45–0.95)
(0.40–0.92)
(0.50–0.95)
(0.44–0.88)

0.026
0.019
0.024
0.007

0.37
0.23

(0.16–0.88)
(0.08–0.64)

0.025
0.005

1.03
0.77

(0.60–1.77)
(0.55–1.07)

0.894
0.120

0.62
0.50

(0.24–1.59)
(0.21–1.14)

0.326
0.102

1.33
1.46
2.04
1.36

(0.90–1.96)
(1.00–2.14)
(1.07 –3.91)
(0.92–2.00)

0.143
0.048
0.030
0.122

1.71
1.38

(0.61–4.76)
(0.61–3.08)

0.299
0.432

Note. AOR ¼ adjusted odds ratio; CI ¼ confidence interval; ART ¼antiretroviral therapy.
a
Separate analyses were done for each item of the perceived family support scale, adjusting for ART
duration, history of illicit drug use in the past six months, and depressive symptoms.
b
Each individual item was assessed as a continuous variable.

recruitment strategy (community-based approach in our study vs. clinic-based
approach in the other) might explain the discrepancies in these ﬁndings.
Regardless, the implications of our ﬁndings are that HIV-positive individuals
would beneﬁt from family support for better adherence over time.
In our study, the rate of nonadherence was higher among those HIV-positive
individuals reporting a history of any illicit drug use compared with those without such a history. Consistent with our results, previous studies have also
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reported an association between illicit drug use and ART nonadherence among
HIV-positive individuals.57–60 This ﬁnding is not surprising, as current illicit
drug use is likely to be associated with disruptions in daily activities, thereby
leading to greater chance of failure to take antiretroviral medicines. This suggests the need to provide particular support to HIV-positive individuals with a
history of illicit drug use to improve their medication adherence.

Limitations
Some limitations should be considered when interpreting our ﬁndings. First, we
used cross-sectional data for this study and thus cannot infer causality.
Longitudinal studies would be necessary to establish clear causal relationships.
Second, as our measurements of ART adherence and other variables are based
on self-report, participants’ responses might have been inﬂuenced by a social
desirability bias, despite our eﬀorts to minimize such bias by assuring participants of the conﬁdentiality of their information. Third, our study is based on
participants’ perceived rather than an objective measure of family support,
though the distinction may not actually be of real concern, as previous studies
have reported an even more important role for perceived support than network
size or received support in inﬂuencing health and adjustment criteria.61,62
Finally, caution is necessary in generalizing our study ﬁndings to the country’s
HIV-positive population as a whole, as our study participants do not represent a
random sample of HIV-positive individuals in the study area. More speciﬁcally,
our ﬁndings are applicable to individuals included in the networks of support
groups providing services to the HIV-positive population at the community level,
as commonly exist in resource-limited countries in Asia and other regions.

Conclusions
Positive family support in the form of perceived emotional support was associated with higher levels of ART adherence, whereas negative family interactions
in the form of family-inﬂicted physical harm and higher levels of felt emotional
distance from family were associated with increased risk of ART nonadherence
among HIV-positive individuals in the Kathmandu Valley, Nepal.
Our ﬁndings have important implications for the design and testing of ART
adherence support interventions involving family members. Involving families of
HIV-positive individuals with high levels of perceived emotional support in
adherence support interventions might improve ART adherence. The goal of
the involvement of family members in such cases should be towards building on
strengths. On the other hand, involvement of the families of those with more
frequent experience of family-inﬂicted physical harm or higher levels of felt
emotional distance from family in adherence support interventions might be
more appropriate only with participants’ prior consent. The focus of the
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involvement of family members in such cases, however, should be geared toward
mitigating the harms. Our results may also be of interest to clinicians or other
health-care providers assisting HIV-positive individuals who are on ART.
Furthermore, our results would be useful in designing training programs for
outreach workers involved in providing home-based care services to HIV-positive individuals. However, further longitudinal studies on the role of family
support in improving ART adherence among HIV-positive individuals are
warranted.
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